Ibogaine gains traction among conservative leaders

Ibogaine, a psychedelic drug derived from an African shrub, is gaining traction among conservative leaders in the United States, according to a recent report by the New Yorker. Former Texas Governor Rick Perry and Kentucky lawyer Bryan Hubbard are at the forefront of efforts to legitimize ibogaine, particularly for treating veterans with PTSD and traumatic brain injuries.

Conservative support for ibogaine

Rick Perry, who has rebranded himself as a proponent of psychedelic therapies, is actively involved in promoting ibogaine. Perry, chairman of Americans for Ibogaine, has described his mission as bringing the drug into mainstream medical use, aligning it with patriotic and Christian values. This approach has helped garner support from red-state governments and secure funding for research.

Bryan Hubbard, co-founder of Americans for Ibogaine, has also been pivotal in this movement. After witnessing the opioid crisis's impact in Kentucky, Hubbard became an advocate for alternative rehabilitation therapies. His efforts have included organizing public hearings and collaborating with researchers and veterans to highlight ibogaine's potential benefits.

Legislative and financial backing

In June 2025, Texas Governor Greg Abbott signed Senate Bill 2308, establishing a framework for ibogaine clinical trials. The bill, which passed overwhelmingly in both the Texas House and Senate, allocates $50 million for these trials. This funding comes from partnerships between the state and private drug developers, with institutions like UTHealth Houston leading the research.

The executive order signed by President Donald Trump in April 2025 further accelerated the push for ibogaine research. The order directs federal agencies to improve coordination and reduce delays in psychedelic clinical trials, specifically mentioning ibogaine. While the order's provisions are largely symbolic, they have raised the profile of ibogaine research.

Why it matters

The increasing support for ibogaine among conservative leaders marks a significant shift in the political landscape surrounding psychedelics. Traditionally associated with counterculture movements, psychedelics are now being reframed as potential medical interventions. This shift could lead to broader acceptance and integration of psychedelic therapies in mainstream healthcare.

The focus on veterans as a sympathetic constituency has been crucial in gaining bipartisan support. By positioning ibogaine as a treatment for valued members of society, advocates hope to overcome the stigma associated with psychedelic drugs.

Challenges and future prospects

Despite the growing support, challenges remain. The scientific research on ibogaine is still limited, and concerns about its cardiotoxicity persist. However, ongoing efforts to develop safer protocols and alternative derivatives continue.

As more states consider pro-psychedelic legislation, the movement's success in Texas could serve as a model for others. With 19 states having passed or pending legislation, the potential for ibogaine to become a widely accepted treatment is growing.

The evolving narrative around ibogaine reflects broader changes in how society views psychedelics, with implications for public health and drug policy.